{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-042728","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2024-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.146685+00:00","generated_at":"2026-05-30T15:28:30.055369+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"C4 Therapeutics board requires shareholder approval for stock option repricing","bullets":["Board approved Amendment No. 1 to the 2020 Stock Option and Incentive Plan on Oct 7, 2024.","Amendment requires stockholder approval for any reduction in exercise price or repricing of stock options or SARs.","Previous administrator authority to reprice without stockholder approval is removed.","Amendment is effective immediately and does not require stockholder approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-042728","json":"https://secwatch.observer/filing/0001628280-24-042728.json","markdown":"https://secwatch.observer/filing/0001628280-24-042728.md","text":"https://secwatch.observer/filing/0001628280-24-042728.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024042728/0001628280-24-042728-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024042728/cccc-20241011.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T15:28:30.055369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}